BAX Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 5.19% compared to Baxter International's net margin of 11.12%. Baxter International's return on equity of 1.33% beat Boston Scientific's return on equity of 8.91%.

Baxter International has a consensus price target of --, signalling upside risk potential of 37.94%. On the other hand Boston Scientific has an analysts' consensus of $99.00 which suggests that it could grow by 11.3%. Given that Baxter International has higher upside potential than Boston Scientific, analysts believe Baxter International is more attractive than Boston Scientific.

Baxter International has a beta of 0.575, which suggesting that the stock is 42.462% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 3.53%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays 22.06% of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.7B, which are smaller than Boston Scientific quarterly revenues of $4.2B. Baxter International's net income of $140M is lower than Boston Scientific's net income of $468M. Notably, Baxter International's price-to-earnings ratio is 147.50x while Boston Scientific's PE ratio is 73.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 0.87x versus 8.29x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 5.19% compared to Baxter International's net margin of 8.28%. Baxter International's return on equity of 1.33% beat Globus Medical's return on equity of 2.27%.

Baxter International has a consensus price target of --, signalling upside risk potential of 37.94%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 14.04%. Given that Baxter International has higher upside potential than Globus Medical, analysts believe Baxter International is more attractive than Globus Medical.

Baxter International has a beta of 0.575, which suggesting that the stock is 42.462% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 3.53%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays 22.06% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Baxter International's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.7B, which are larger than Globus Medical quarterly revenues of $625.7M. Baxter International's net income of $140M is higher than Globus Medical's net income of $51.8M. Notably, Baxter International's price-to-earnings ratio is 147.50x while Globus Medical's PE ratio is 123.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 0.87x versus 4.57x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of 5.19% compared to Baxter International's net margin of 9.79%. Baxter International's return on equity of 1.33% beat Haemonetics's return on equity of 13.51%.

Baxter International has a consensus price target of --, signalling upside risk potential of 37.94%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 46.87%. Given that Haemonetics has higher upside potential than Baxter International, analysts believe Haemonetics is more attractive than Baxter International.

Baxter International has a beta of 0.575, which suggesting that the stock is 42.462% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 3.53%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays 22.06% of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend. Baxter International's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.7B, which are larger than Haemonetics quarterly revenues of $345.5M. Baxter International's net income of $140M is higher than Haemonetics's net income of $33.8M. Notably, Baxter International's price-to-earnings ratio is 147.50x while Haemonetics's PE ratio is 31.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 0.87x versus 2.85x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of 5.19% compared to Baxter International's net margin of 20.32%. Baxter International's return on equity of 1.33% beat LeMaitre Vascular's return on equity of 13.37%.

Baxter International has a consensus price target of --, signalling upside risk potential of 37.94%. On the other hand LeMaitre Vascular has an analysts' consensus of $98.78 which suggests that it could grow by 7.22%. Given that Baxter International has higher upside potential than LeMaitre Vascular, analysts believe Baxter International is more attractive than LeMaitre Vascular.

Baxter International has a beta of 0.575, which suggesting that the stock is 42.462% less volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.665%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 3.53%. LeMaitre Vascular offers a yield of 0.7% to investors and pays a quarterly dividend of $0.16 per share. Baxter International pays 22.06% of its earnings as a dividend. LeMaitre Vascular pays out 41.35% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.7B, which are larger than LeMaitre Vascular quarterly revenues of $54.8M. Baxter International's net income of $140M is higher than LeMaitre Vascular's net income of $11.1M. Notably, Baxter International's price-to-earnings ratio is 147.50x while LeMaitre Vascular's PE ratio is 50.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 0.87x versus 9.79x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.